Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-11-13

Clinical Trial Update: OPALINE : A Study Of Morbidity And Mortality At 2 Years

View source ↗

Summary

Clinical trial update for OPALINE reports morbidity and mortality outcomes at 2 years in well-differentiated, progressive pancreatic neuroendocrine tumor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OPALINE

Snippet

Sponsor: Pfizer | Conditions: Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive | Status: COMPLETED | Results posted: 2023-11-13